Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Regular Use of Proton Pump Inhibitor and the Risk of Inflammatory Bowel Disease: Pooled Analysis of 3 Prospective Cohorts
Bin Xia, Man Yang, Long H. Nguyen, et al.
Gastroenterology (2021) Vol. 161, Iss. 6, pp. 1842-1852.e10
Open Access | Times Cited: 65

Showing 1-25 of 65 citing articles:

Sugar‐sweetened beverages, artificially sweetened beverages and natural juices and risk of inflammatory bowel disease: a cohort study of 121,490 participants
Tian Fu, Hui Chen, Xuejie Chen, et al.
Alimentary Pharmacology & Therapeutics (2022) Vol. 56, Iss. 6, pp. 1018-1029
Open Access | Times Cited: 41
Compared to histamine-2 receptor antagonist, proton pump inhibitor induces stronger oral-to-gut microbial transmission and gut microbiome alterations: a randomised controlled trial
Jiaying Zhu, Chuqing Sun, Min Li, et al.
Gut (2023) Vol. 73, Iss. 7, pp. 1087-1097
Open Access | Times Cited: 22
Approach to the diagnosis and management of dysbiosis
Kannayiram Alagiakrishnan, Joao Morgadinho, Tyler Halverson
Frontiers in Nutrition (2024) Vol. 11
Open Access | Times Cited: 9
Regulatory effects of oral microbe on intestinal microbiota and the illness
Yanbei Lu, Zhengyi Li, Xian Peng
Frontiers in Cellular and Infection Microbiology (2023) Vol. 13
Open Access | Times Cited: 21
Proton pump inhibitors may enhance the risk of digestive diseases by regulating intestinal microbiota
Tian Liang, Chongfei Huang, Wenkang Fu, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 20
Individualized prevention of proton pump inhibitor related adverse events by risk stratification
Bin Xia, Qiangsheng He, Fang Gao Smith, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 7
Manipulation of Gut Microbiota as a Key Target for Crohn's Disease
Reem Rashed, Rosica Valcheva, Levinus A. Dieleman
Frontiers in Medicine (2022) Vol. 9
Open Access | Times Cited: 22
Proton pump inhibitors and the risk of inflammatory bowel disease: population-based cohort study
Devin Abrahami, Richeek Pradhan, Hui Yin, et al.
Gut (2023) Vol. 72, Iss. 7, pp. 1288-1295
Closed Access | Times Cited: 14
Impact of Helicobacter pylori Eradication on Inflammatory Bowel Disease Onset and Disease Activity: To Eradicate or Not to Eradicate?
Antonietta Gerarda Gravina, Raffaele Pellegrino, Veronica Iascone, et al.
Diseases (2024) Vol. 12, Iss. 8, pp. 179-179
Open Access | Times Cited: 5
The potential of EGCG in modulating the oral-gut axis microbiota for treating inflammatory bowel disease
Jiaming Ge, Mengyuan Li, Jingwen Yao, et al.
Phytomedicine (2024) Vol. 130, pp. 155643-155643
Closed Access | Times Cited: 4
Effects of proton pump inhibitors on inflammatory bowel disease: An updated review
Liang Yu, Zhen Meng, Xueli Ding, et al.
World Journal of Gastroenterology (2024) Vol. 30, Iss. 21, pp. 2751-2762
Open Access | Times Cited: 4
The Role of Environmental Factors Prior to Diagnosis on the Activity and Severity of Inflammatory Bowel Diseases—Results From the Prospective Population‐Based Copenhagen Inflammatory Bowel Disease Inception Cohort
Mohamed Attauabi, G R Madsen, Flemming Bendtsen, et al.
United European Gastroenterology Journal (2025)
Open Access
Effects of proton pump inhibitor (PPI) use on migraine – a critical review
Viktoria Tischler-Strasser, Irma Burdiladze, Gonçalo Cabral, et al.
The Journal of Headache and Pain (2025) Vol. 26, Iss. 1
Open Access
Prevalence and Risk Factors Associated With Inflammatory Bowel Disease in Patients Using Proton-Pump Inhibitors: A Population-Based Study
Somtochukwu Onwuzo, Antoine Boustany, Hadi Khaled Abou Zeid, et al.
Cureus (2023)
Open Access | Times Cited: 12
GLP-1 Receptor Agonists in Obese Patients with Inflammatory Bowel Disease: from Molecular Mechanisms to Clinical Considerations and Practical Recommendations for Safe and Effective Use
Konstantinos Arvanitakis, Theocharis Koufakis, Djordje S. Popovic, et al.
Current Obesity Reports (2023) Vol. 12, Iss. 2, pp. 61-74
Closed Access | Times Cited: 11
Eosinophils, Eosinophilic Gastrointestinal Diseases, and Inflammatory Bowel Disease: A Critical Review
Giulia Migliorisi, Elisabetta Mastrorocco, Arianna Dal Buono, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 14, pp. 4119-4119
Open Access | Times Cited: 4
Novel Potassium-Competitive Acid Blocker, Tegoprazan, Protects Against Colitis by Improving Gut Barrier Function
Mijeong Son, I Seul Park, Soochan Kim, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 16
Long-Term Use of Proton Pump Inhibitors Disrupts Intestinal Tight Junction Barrier and Exaggerates Experimental Colitis
Meghali Nighot, Pei-Luan Liao, Nathan M. Morris, et al.
Journal of Crohn s and Colitis (2022) Vol. 17, Iss. 4, pp. 565-579
Open Access | Times Cited: 16
Proton-Pump Inhibitors Suppress T Cell Response by Shifting Intracellular Zinc Distribution
Wenlei Liu, Jana Jakobs, Lothar Rink
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 2, pp. 1191-1191
Open Access | Times Cited: 10
Influence of proton pump inhibitor use on clinical outcomes of patients with inflammatory bowel disease
Tenzin Choden, Zhang Hui, Atsushi Sakuraba
Annals of Medicine (2023) Vol. 55, Iss. 1
Open Access | Times Cited: 10
Proton Pump Inhibitor Use Before and After a Diagnosis of Inflammatory Bowel Disease
Noreen Singh, Zoann Nugent, Harminder Singh, et al.
Inflammatory Bowel Diseases (2023) Vol. 29, Iss. 12, pp. 1871-1878
Closed Access | Times Cited: 9
Co-Administration of Proton Pump Inhibitors May Negatively Affect the Outcome in Inflammatory Bowel Disease Treated with Vedolizumab
Kata Szemes, Nelli Farkas, Zoltan Sipos, et al.
Biomedicines (2024) Vol. 12, Iss. 1, pp. 158-158
Open Access | Times Cited: 3
Malate initiates a proton-sensing pathway essential for pH regulation of inflammation
Yujianan Chen, Ruihua Shi, Yan Xiang, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 3
Absolute and Relative Risks of Kidney and Urological Complications in Patients With Inflammatory Bowel Disease
Yuanhang Yang, Jonas F. Ludvigsson, Ola Olén, et al.
The American Journal of Gastroenterology (2023) Vol. 119, Iss. 1, pp. 138-146
Closed Access | Times Cited: 7
Healthy eating patterns associated with reduced risk of inflammatory bowel disease by lowering low-grade inflammation: evidence from a large prospective cohort study
Bin Xia, Yan Li, Linmin Hu, et al.
BMC Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top